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Use of plasma DNA to detect mutations has spread widely as a form of liquid
biopsy. EGFR T790M has been observed in half of lung cancer patients who have
acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI). Effectiveness of
monitoring T790M via plasma DNA during treatment with EGFR-TKI has not been
established as an alternative to re-biopsy. This was a prospective multicenter
observational study involving non-small cell lung cancer patients carrying EGFR
L858R or exon 19 deletions, treated with EGFR-TKI. The primary objective was to
determine whether T790M could be detected using plasma DNA in patients with
progressive disease (PD). T790M was examined using the mutation-biased PCR
and quenching probe (MBP-QP) method, a sensitive, fully-automated system
developed in our laboratory. Eighty-nine non-small cell lung cancer patients were
enrolled from seven hospitals in Japan. Sequential examinations revealed T790M
in plasma DNA among 40% of patients who developed PD. Activating mutations,
such as L858R and exon 19 deletions, were detected in 40% of patients using
plasma DNA, and either T790M or activating mutations were observed in 62%.
Dividing into four periods (before PD, at PD, at discontinuation of EGFR-TKI and
subsequently), T790M was detected in 10, 19, 24 and 27% of patients, respec-
tively. Smokers, males, patients having exon 19 deletions and patients who
developed new lesions evidenced significantly frequent presence of T790M in
plasma DNA. Monitoring T790M with plasma DNA using MBP-QP reflects the clin-
ical course of lung cancer patients treated with EGFR-TKI. Detection of T790M
with plasma DNA was correlated with EGFR mutation type, exon 19 deletions
and tumor progression. Re-biopsy could be performed only in 14% of PD cases,
suggesting difficulty in obtaining re-biopsy specimens in practice. Monitoring
T790M with plasma DNA reflects the clinical course, and is potentially useful in
designing strategies for subsequent treatment.
C ompanion diagnostics has seen growing importance, espe-cially for molecular targeted therapy such as EGFR tyro-
sine kinase inhibitors (EGFR-TKI) in lung cancer. Recently, a
second generation EGFR-TKI, afatinib, evidenced a potent
anti-cancer effect against lung cancer cells harboring
T790M,(1) but the anti-cancer effect in a phase 2b ⁄3 random-
ized trial was unsatisfactory considering the results of preclini-
cal studies.(2) Because examination of biomarkers related to
acquired resistance to EGFR-TKI was not performed in that
trial, it is speculated that the patients included those with can-
cers possessing various mechanisms of acquired resistance to
EGFR-TKI. Recently, third generation EGFR-TKI, such as
AZD9291 and CO-1686, have shown potent anti-cancer effects
in T790M positive non-small cell lung cancer patients.(3,4)
Considering this evidence, examination of biomarkers is indis-
pensable for accurate assessment of anti-cancer effects, and
timely monitoring of genetic alterations is necessary for deter-
mining appropriate treatment.
The use of circulating free DNA to detect genetic alter-
ations, so called “liquid biopsy,” has spread worldwide.(5–9)
For the purpose of molecular diagnosis before treatment, eval-
uation of genetic alterations should be comprehensive to pick
up changes specific to each individual using deep sequencing
or a multiplex system.(7–9) For monitoring therapeutic effects,
we can focus on the specific loci of genetic changes such as
T790M mutation. Because repeated examinations are needed
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for monitoring, the ideal detection system should be simple,
automated and non-invasive.
We have developed a fully-automated sensitive mutation
detection system, the mutation-biased PCR and quenching probe
(MBP-QP) method, for detection of EGFR T790M mutations
with plasma DNA.(10) The detection limit is two copies, and the
sensitivity is 0.3%. Our retrospective study showed that T790M
mutation was detected in plasma DNA in 53% of lung adenocar-
cinoma patients who acquired resistance to EGFR-TKI, and
monitoring of T790M using MBP-QP was reflective of the clini-
cal course in lung cancer patients treated with EGFR-TKI.(10)
Based on these results, we proceeded to a prospective multicen-
ter observational study. The purpose of this investigation was to
determine whether T790M detection using MBP-QP with
plasma DNA is useful for monitoring acquired resistance to
EGFR-TKI, and to assess the possibility of using the method to
predict efficacy of EGFR-TKI targeted to T790M.
Patients and Methods
Study population. This study, the Hanshin-Saga T790M
(HASAT) study, was a prospective multicenter observational
study. Patients were recruited from seven hospitals in Japan
between 1 February 2011 and 29 February 2012. All hospitals
belonged to the Hanshin-Saga Collaborative Cancer Study
Group, a Japanese non-profit organization. Eligibility criteria
were a diagnosis of non-small cell lung cancer confirmed by
histological or cytological examination with exon 19 deletions
and L858R in patients who were scheduled to start, or had
already begun, treatment with EGFR-TKI. Patients had mea-
surable or non-measurable diseases according to the Response
Evaluation Criteria in Solid Tumors (RECIST).(11) Patients
were not eligible to participate if T790M was detected in can-
cer tissues or cells before EGFR-TKI treatment. Ascertainment
of EGFR mutations including T790M before entry into the
study was performed in one of two commercial clinical labora-
tories, SRL (Tokyo, Japan) or Mitsubishi Chemical Medience
Corporation (Tokyo, Japan), and was covered by medical
insurance. Detection methods were cycleave PCR techniques
and peptide nucleic acid-locked nucleic acid PCR clamp,
respectively. All patients provided written informed consent.
Study design. Detection of T790M in plasma DNA was per-
formed using the MBP-QP method, as described previously.(10)
Briefly, 200 lL of plasma was subjected to DNA isolation
using a QIAamp DNA Mini Kit (QIAGEN, Hilden, Ger-
many), and 4 lL of purified DNA water was applied to MBP-
QP, a fully automated detection system. Negative and positive
controls were added to each examination. The analyses were
performed using i-densy, and the areas under the mutation
peaks were determined by the “idensy AreaAna” software
(ARKRAY, Kyoto, Japan). T790M positivity was declared if
the area was 8.0 or more. Examinations of T790M in plasma
DNA were performed before treatment with EGFR-TKI and
every 4 months after the start of treatment. Chest CT and
tumor markers were examined every 2 months. These exami-
nations were also performed upon detection of progressive dis-
ease (PD) and at discontinuation of EGFR-TKI, and after two
courses of post-chemotherapy, as well as 1 month after starting
EGFR-TKI to check T790M at the peak response time. PD
was evaluated by each investigator, and central review was
carried out to confirm these evaluations. Re-biopsy was
requested but not mandatory. T790M was examined by MBP-
QP using tissue specimens obtained before treatment with
EGFR-TKI and at the time of PD. The primary objective was
to investigate whether T790M can be detected in plasma DNA
at the time of PD, and the secondary objective was to confirm
the correspondence between T790M levels in plasma and can-
cer specimens. A further exploratory objective was to verify
the association between detection of T790M and the effect of
EGFR-TKI. The criteria of T790M detection at the time of PD
was that T790M should be detected from 30 days before to
70 days after PD considering the interval in which plasma
samples were collected. Activating mutations, such as exon 19
deletions and L858R, were also examined in plasma DNA
using the wild inhibiting PCR and quenching probe system
(WIP-QP) and MBP-QP method, respectively, which were
modified versions of those reported previously.(12) These
examinations were performed using the same plasma DNA in
which T790M was detected. In T790M negative cases, the
samples were obtained at the time of PD for patients who
acquired resistance to EGFR-TKI, and for non-PD cases the
samples were those obtained at the end of follow up.
Statistical analysis. The association between T790M status in
plasma DNA and clinical parameters was tested using the v2-
test for categorical data and the t-test for continuous data. The
survival rate was calculated according to the Kaplan–Meier
method with differences assessed using the log rank test. Cox
proportional hazards regression analysis was used to calculate
the hazard ratio and the 95% confidence interval (CI) of the
survival outcome of lung cancer patients. P-values are two-
tailed; those below 0.05 were considered statistically signifi-
cant. All statistical analyses were conducted using IBM SPSS
Statistics 19 (SPSS, IBM, Tokyo, Japan).
Results
Patient characteristics. Out of 90 patients assessed for eligi-
bility, 1 was excluded for lack of measurable and non-measur-
able lesions (Fig. S1). Characteristics of the 89 registered
patients are shown in Table S1. The number of recruited
patients having exon 19 deletions or L858R mutation was sim-
ilar. Among the 89 patients, 83% had no history of EGFR-TKI
treatment, whereas the remaining 17% had received prior
EGFR-TKI. Although patients with cancer harboring T790M,
which was examined in our own hospital, were excluded,
T790M was detected in 5 of 77 samples (6.5%) that were
available for re-examination using MBP-QP. Because 2 of the
89 patients died before plasma samples could be collected, 87
patients were analyzed. A total of 58 patients developed PD,
in 23 of whom T790M was detected in plasma DNA. Dividing
into two groups, with or without a history of EGFR-TKI treat-
ment, T790M was detected in 18 of 47 patients (35%) among
those who were EGFR-TKI na€ıve, and in 5 of 11 (45%)
among those previously treated with EGFR-TKI. T790M was
detected in 7 of 29 patients with non-PD. Re-examination of
T790M in cancer tissue samples before EGFR-TKI treatment
using MBP-QP revealed positivity in 5.9 and 7.7% among the
patients whose diseases developed PD or not, respectively.
Profile of T790M detection with plasma DNA. T790M was
detected in 23 of 58 patients (40%) whose diseases developed
PD (Table 1). Dividing into four time periods (before PD, at
PD, at discontinuation of EGFR-TKI and subsequently), T790M
was detected in 10, 19, 24 and 27% of cases, respectively.
T790M was first detected anywhere from 11 months before PD
to 9 months after (Fig. S2): at PD in 39% (9 ⁄23), and at or after
PD in 74% (17 ⁄23). Activating mutations were detected overall
in 40% (35 ⁄87) of patients in this study; exon 19 deletions were
detected in 41% (18 ⁄44) of patients and L858R in 40% (17 ⁄43).
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Among the patients who acquired resistance to EGFR-TKI, both
T790M positivity and activating mutations were detected in
22% (Table S2), and T790M positive only or activating muta-
tion only were detected in 17 and 22%, respectively. The pro-
portion with either T790M positive or activating mutation was
62%. According to other work, T790M was detected, but acti-
vating mutations sometimes disappeared with re-biopsy speci-
mens isolated from the patients who acquired resistance to
EGFR-TKI.(13) These results suggest that a clone of cancer cells
carrying T790M exists after acquired resistance. The profiles of
T790M positive patients who developed PD are shown in Fig-
ure 1. T790M was detected once in 16 patients and twice or
more in 7 patients. Among the former, T790M was mostly
detected after PD in 13 of 16 patients. For Patient No. 7,
T790M was also detected in the cancer specimens before
EGFR-TKI treatment using MBP-QP. Because the relative
amount of mutant allele can be estimated by determination of
the area under the mutation peak, we evaluated the relationship
between the amount of mutant and clinical course (Fig. S3). In
the cases in which T790M was detected twice or more, the area
under the mutation peak tended to be chronologically increas-
ing. Comparing PD and non-PD, the amount of mutant allele
tended to be higher in PD, except in 1 patient, No 28. Among
the patients with non-PD, T790M was detected in 7 patients
(Fig. S4). T790M was positive at the end of the follow-up per-
iod in 3 patients, and it was repeatedly detected in 1 patient. In
Patient No. 30, T790M was repeatedly detected at the end of
the follow-up period, at which time T790M was also detected in
the primary lesion, suggesting that the T790M positive clone
expanded.
Concordance of T790M detection between plasma DNA and re-
biopsy specimens. We obtained eight re-biopsy specimens,
including primary lesions from 3 patients, intrapulmonary
metastases from 3 patients and pleural effusions from 2
patients (Table 2). T790M was detected in 4 and 2 patients
from re-biopsy and plasma DNA, respectively. As for the case
in which T790M was positive in both samples, re-biopsy was
taken from the primary lesion. The samples positive for
T790M only in re-biopsy were from one primary lesion and
two intrapulmonary metastatic lesions, and the case that was
positive for T790M only in plasma DNA was for a re-biopsy
from pleural effusion.
Clinical characteristics of patients with progressive disease:
Comparing T790M positive and negative patients. T790M was
more frequently detected in males, smokers and patients with
exon 19 deletions (Table 3). Moreover, T790M was detected
frequently when new lesions developed, but less frequently in
the case of mere exacerbation of target lesions such as primary
lesions and ⁄or lymph node metastasis. Two of three T790M
positive patients who developed PD manifesting as an increase
in target lesions showed enlargement of metastatic lesions in
the liver or adrenal gland. These results indicate that detection
of T790M in plasma DNA was related to distant metastasis.
Comparing overall survival (OS) between patients who were
T790M positive versus negative among those who developed
PD, the group negative for T790M evidenced significantly pro-
longed OS (median, 516 days vs 782 days; hazard ratio for
death with T790M positive in plasma DNA, 2.15; 95% CI,
1.11–4.14; P = 0.020) (Fig. 2a). Combined analysis of T790M
and activating mutations with plasma DNA showed that having
neither T790M nor activating mutations was associated with
better prognosis than having both T790M and activating muta-
tion or either alone (median, 807 days vs 509 days; hazard
ratio for death with neither T790M nor activating mutation in
plasma DNA, 0.240; 95% CI, 0.104–0.553; P = 0.010)
(Fig. 2b).
Discussion
In this prospective study, we observed the following. First,
monitoring T790M in plasma DNA using MBP-QP is feasible,
and it reflects the clinical course of lung cancer patients with
L858R or exon 19 deletions treated with EGFR-TKI. Second,
detection of T790M with plasma DNA is not correlated with
the effect of EGFR-TKI, but with EGFR mutation type,
Table 1. Detection of T790M with plasma DNA among the patients
who developed PD
Total 23 ⁄ 58 patients (40%)
Before PD 6 ⁄ 58† (10%)
at PD 10 ⁄ 54† (19%)
at discontinuation 11 ⁄ 45† (24%)
After discontinuation 10 ⁄ 37† (27%)
†The ratio was calculated as number T790M positive ⁄ number of sam-
ples obtained. PD, progressive disease.
Fig. 1. Monitoring T790M with plasma DNA
among patients who developed progressive disease
(PD). Serial analysis of T790M with plasma DNA
among patients with PD is shown. Time is time
from PD as baseline. Open circles and filled circles
indicate T790M negative and positive, respectively.
Our criterion of PD was from 30 days before to
70 days after PD (dotted line) considering that
blood collection was every 4 months. 9,
discontinuation of EGFR-TKI; PD, progressive disease
as tumor response of chemotherapy; primary
T790M, T790M status in primary lesions; re-biopsy
T790M, T790M status in re-biopsy specimens; SD,
stable disease as tumor response of chemotherapy.
Green line: period of chemotherapy.
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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exon 19 deletions and tumor progression. Finally, re-biopsy
can be performed in only a small fraction of patients with PD,
and concordance with re-biopsy is approximately half.
T790M was detected in plasma DNA in 40% of the 58
patients whose diseases developed PD. Activating mutations
were detected in 40%, and either T790M or activating muta-
tions was present in 62%, suggesting that tumor-derived DNA
was contained in peripheral blood of at least 62% of the study
population. Monitoring T790M with plasma DNA showed that
frequency of T790M detection increased following the onset of
PD. The first detection period was mostly clustered around the
time of PD and afterwards, and the area under the mutation
peak increased with the passage of time, indicating that the
results of T790M reflect the clinical course in the population.
In addition, T790M was more frequently detected in the PD
patients with previous EGFR-TKI treatment compared to those
who were EGFR-TKI na€ıve, suggesting that T790M appears in
plasma as the tumor progresses. When T790M was sporadi-
cally detected before PD, the amount of T790M estimated by
the area under the mutation curve was relatively small. These
data suggest that fluctuation in the detected level of T790M
occurs because of the low copy number in peripheral blood.
According to previous findings, T790M existing in cis with
activating mutations such as L858R and exon 19 deletions
induced transforming activity in vitro and led to tumor forma-
tion in animal experiments, suggesting that T790M has onco-
genic activity.(14) In the clinical situation, lung cancer patients
who were T790M positive in re-biopsy showed better progno-
sis compared to those who were T790M negative,(13,15) sug-
gesting that T790M positive clones may be less aggressive.
However, in a retrospective study, we reported that T790M
positivity in plasma DNA showed poorer prognosis compared
to T790M negativity.(10) That result was confirmed in the pre-
sent work. We showed also in the present study that the detec-
tion rate and amount of T790M increased as tumors
developed. In addition, T790M was frequently detected when
new lesions, mostly distant metastases, appeared. Combined
analysis of T790M and activating mutations showed that the
presence of either mutation (or both) resulted in poor progno-
sis. Considering all of these findings together, T790M itself
does not seem to have strong metastatic potential, but the
appearance of DNA derived from tumor in peripheral blood is
correlated with tumor progression, including metastasis.
Tumor-derived DNA has been thought to be released into
peripheral blood after necrosis and ⁄or apoptosis, but mainly
necrosis, and it has been assumed to be related to tumor bur-
den, stage and cellular turnover.(16,17) Recent data from animal
studies in our laboratory indicate that the amount of tumor-
derived DNA is related to aspects of tumor progression, such
as metastasis.(18)
The effects of EGFR-TKI, such as best response, duration of
treatment and progression-free survival, were not correlated
with detection of T790M in plasma. In contrast, T790M in
plasma was frequently observed in smokers, males and patients
with exon 19 deletions. These results suggest that appearance
of T790M in plasma is related to biological characteristics of
lung cancer, but not status of treatment with EGFR-TKI.
T790M was detected more frequently in lung cancers carrying
exon 19 deletions even with re-biopsy.(19) According to a pre-
vious report, biological characteristics differed between
exon 19 deletions and L858R when T790M coexisted with
each mutation.(14) Catalytic and tumorigenic activity with a
combination of T790M with exon 19 deletions was more
aggressive than that with L858R. Formation of tumors carrying
T790M and exon 19 deletions was more rapidly growing than
Table 2. Concordance between plasma DNA and re-biopsy
Age Gender Smoking EGFR mutation
Effect of EGFR-TKI T790M
Best response Reason for PD Plasma Re-biopsy Site of re-biopsy
86 Female Never Exon 19 PD Pleural effusion Negative Negative Pleural effusion
59 Female Never Exon 19 PR Primary lesion Negative Negative Primary lesion
70 Female Smoker Exon 19 PR New lesion Positive Positive Primary lesion
69 Male Never Exon 19 SD New lesion Negative Negative Lung metastasis
65 Female Smoker L858R SD Primary lesion Negative Positive Primary lesion
81 Male Smoker L858R SD Pleural effusion Positive Negative Pleural effusion
66 Male Smoker L858R PR New lesion Negative Positive Lung metastasis
74 Female Never L858R NE Non-PD Negative Positive Primary lesion
NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease
Table 3. Comparison between T790M positive and negative among







Age (median; range) 70 (54–89) 68 (48–88) NS
Gender (%)
Female 12 (32) 26 (68) 0.04
Male 11 (55) 9 (45)
Smoking status (%)
Non-smoker 10 (27) 27 (73) <0.01
Smoker 13 (62) 8 (38)
EGFR mutation (%)
Exon 19 deletions 16 (52) 15 (48) 0.05
L858R 7 (26) 20 (74)
Best response (%)
PR or SD 20 (38) 32 (62) NS
PD 3 (50) 3 (50)
Duration of TKI treatment 400 days 393 days NS
Median PFS 303 days 344 days NS
Reasons for PD (%)
New lesions 12 (52) 11 (48) 0.01
Increase in target lesions 3 (15) 17 (85)
Patient characteristics with or without T790M in plasma were
compared using the v2-test for categorical data and the t-test for
continuous data. NS, not significant; PD, progressive disease; PFS,
progression-free survival; PR, partial response; SD, stable disease; TKI,
tyrosine kinase inhibitor.
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T790M and L858R in the animal model. Considering that
appearance of T790M in plasma is correlated with tumor pro-
gression, it is plausible that coexistence of T790M with
exon 19 deletions is observed more frequently than coexis-
tence of T790M with L858R.
Investigating the concordance between plasma and re-biopsy
was the secondary objective of the present study. However, re-
biopsy samples were obtained from only 14% of patients, all
from intra-thoracic regions. This suggests that re-biopsy is dif-
ficult to perform, especially from distant metastatic sites.
Indeed, reports from other laboratories show that most re-
biopsy is performed from intra-thoracic lesions, including the
enlarging primary lesion, intra-pulmonary lesion and pleural
effusion.(15,20–22) Recently, inter-tumor and intra-tumor hetero-
geneity has been reported.(23,24) In addition to different geno-
mic alterations between primary and metastatic lesions, spatial
variation in the primary lesion has also been reported. Investi-
gation of T790M and MET amplification in each primary and
metastatic lesion after acquired resistance revealed inconsisten-
cies, suggesting that inter-tumor heterogeneity occurs after
treatment with EGFR-TKI.(24) Although re-biopsy has been the
gold standard to assess the mechanism of acquired resistance
to EGFR-TKI, these reports indicate that a single biopsy can-
not reflect genomic alterations throughout the tumors in each
patient. A recently published paper showed that the concor-
dance between re-biopsy and liquid biopsy including plasma
DNA and circulating tumor cell was 57–60%.(25) Based on evi-
dence from whole-genome sequencing, somatic mutations in
plasma DNA were detected from 21 to 55% of mutations
detected in corresponding tumor DNA. The detection rate of
mutations observed in the primary lesion was low, while that
of metastatic lesions was high in plasma DNA.(26) These
results indicate that detection of mutations in plasma DNA
reflects approximately half of the mutations occurring in
tumors, and inter-tumor and intra-tumor heterogeneity may be
the cause of disagreement in mutation status between re-biopsy
and liquid biopsy.
Monitoring of T790M in plasma DNA could assist us in
designing strategies for subsequent treatment. To confirm that
plasma DNA reflects dominant genomic alterations, it is neces-
sary to investigate the anti-cancer effect of T790M inhibitors
using detection of T790M with plasma DNA as a biomarker.
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